How is chronic synovitis best treated?

Chronic synovitis—the persistent inflammation of the synovial membrane lining joints—requires a comprehensive, individualized treatment approach aimed at reducing inflammation, preserving joint structure and function, and addressing underlying causes. First-line management typically includes nonsteroidal anti-inflammatory drugs (NSAIDs) to alleviate pain and suppress inflammatory mediators. For patients with moderate-to-severe disease or inadequate response to NSAIDs, disease-modifying antirheumatic drugs (DMARDs), such as methotrexate or sulfasalazine, are often initiated—especially when chronic synovitis is associated with autoimmune conditions like rheumatoid arthritis or psoriatic arthritis.

Corticosteroid injections into the affected joint provide rapid, localized anti-inflammatory effects and are particularly useful for monoarticular or oligoarticular involvement. In refractory cases, biologic DMARDs—including tumor necrosis factor (TNF) inhibitors (e.g., adalimumab, infliximab), interleukin-6 inhibitors (e.g., tocilizumab), or JAK inhibitors (e.g., tofacitinib)—may be indicated following thorough risk–benefit assessment and screening for infections (e.g., latent tuberculosis) and contraindications.

Nonpharmacologic interventions are equally critical: physical therapy helps maintain range of motion, strengthen periarticular musculature, and improve functional capacity; activity modification and joint protection strategies minimize mechanical stress; and weight optimization in overweight individuals significantly reduces load-related synovial irritation, particularly in weight-bearing joints like the knee and hip.

Underlying triggers must be identified and managed—such as gout (with urate-lowering therapy), infection (requiring appropriate antimicrobials), or crystal-induced arthropathy. In rare, severe, or treatment-resistant cases where synovial hypertrophy leads to mechanical impingement or progressive joint damage, surgical synovectomy—either via arthroscopy or open technique—may be considered after multidisciplinary evaluation.

Long-term monitoring—including clinical assessment, imaging (e.g., ultrasound or MRI to detect synovial hypertrophy and power Doppler signal), and serologic markers—is essential to gauge treatment response, adjust therapy, and prevent irreversible joint damage. A collaborative care model involving rheumatology, physical medicine and rehabilitation, and orthopedics ensures optimal outcomes.